Background Stroke after transcatheter aortic valve implantation (TAVI) is an infrequent but serious complication with ...
PARTNER 3 may notch a win for transcatheter aortic valve replacement in patients with low surgical risk, according to experts ...
Low-risk patients with severe, symptomatic aortic stenosis show similar clinical outcomes and valve durability ...
People living with aortic stenosis (AS) could gain earlier access to innovative care and treatment thanks to a new effort ...
People living with aortic stenosis (AS) could gain earlier access to innovative care and treatment thanks to a new effort from the American Heart Association designed to boost clinical trial ...
Motorists are being alerted to an important date that’s fast-approaching. On social media, the DVLA Personalised Registration ...
TipRanks on MSN
Edwards Lifesciences upgraded to Outperform at Raymond James
Raymond James analyst Jayson Bedford upgraded Edwards Lifesciences (EW) to Outperform from Market Perform with a $96 price ...
Trials from Edwards, Philips and Penumbra were among the most-watched studies at the annual cardiovascular meeting.
Edwards Lifesciences has raised its fiscal year (FY25) guidance to between $2.56 to $2.62 per share after achieving better ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback